Plasmacytoma
Symptoms, Doctors, Treatments, Advances & More

Plasmacytoma Overview

Save information for later
Sign Up

Learn About Plasmacytoma

Who are the top Plasmacytoma Local Doctors?
Elite in Plasmacytoma
Youlia M. Kirova
Elite in Plasmacytoma
Youlia M. Kirova
Referral may be required
Paris, FR 

Youlia Kirova practices practicing medicine in Paris, France. Kirova is rated as an Elite expert by MediFind in the treatment of Plasmacytoma. They are also highly rated in 14 other conditions, according to our data. Their clinical expertise encompasses Breast Cancer, Plasmacytoma, Mediastinal Tumor, Mastectomy, and Hysterectomy.

Elite in Plasmacytoma
Philippe A. Moreau
Elite in Plasmacytoma
Philippe A. Moreau
Referral may be required
Head And Neck, 
Nantes, FR 

Philippe Moreau practices practicing medicine in Nantes, France. Mr. Moreau is rated as an Elite expert by MediFind in the treatment of Plasmacytoma. He is also highly rated in 21 other conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Plasmacytoma, Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Bone Marrow Aspiration.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Plasmacytoma
Dr. Shaji Kumar
Hematology
Elite in Plasmacytoma
Dr. Shaji Kumar
Hematology
Referral may be required

MN - Cancer Transplant

200 1st St SW, 
Rochester, MN 
507-923-2592
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Shaji Kumar is a Hematologist practicing medicine in Rochester, Minnesota. Dr. Kumar is rated as an Elite provider by MediFind in the treatment of Plasmacytoma. He is also highly rated in 13 other conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Smoldering Multiple Myeloma, Plasmacytoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

View All Doctors
What are the latest Plasmacytoma Clinical Trials?
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
Who is this study for: Patients with relapsed/refractory hematological malignances
Enrollment Status: Recruiting
Publish Date: June 08, 2026
Intervention Type: Drug
Study Drugs: Cyclophosphamide, CAR.70/IL15-transduced CB-NK cells, Fludarabine phosphate
Study Phase: Phase 1/Phase 2

Summary: The goal of this clinical research study is to learn about the safety of giving immune cells called natural killer (NK) cells with chemotherapy to patients with leukemia, lymphoma, or multiple myeloma. Immune system cells (such as NK cells) are made by the body to attack foreign or cancerous cells. Researchers think that NK cells you receive from a donor may react against cancer cells in your body...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Frontline Management of High-Risk Multiple Myeloma or Plasmacytoma With BCMA and GPRC5D Combination CAR-T Cell Therapy
Frontline Management of High-Risk Multiple Myeloma or Plasmacytoma With BCMA and GPRC5D Combination CAR-T Cell Therapy
Enrollment Status: Recruiting
Publish Date: April 24, 2026
Intervention Type: Biological
Study Phase: Phase 1/Phase 2

Summary: The aim of this clinical trial is to assess the feasibility, safety, and efficacy of CAR-T cell therapy targeting multiple cancer cell antigens in high-risk multiple myeloma or plasmacytoma as part of a frontline treatment regimen for patients. Another goal of the study is to learn more about the persistence and function of these CAR-T cells in the body.

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 10, 2022
Published By: Genetic and Rare Diseases Informnation Center